Ipsos Extends Lab Mapping Study to Aus

Ipsos Healthcare has announced the Australian launch of its syndicated Lab Mapping Study, already available in the US and the five biggest European markets. The study delivers a comprehensive picture of the laboratories involved in cancer biomarker testing.

The study, a key component of the group's Oncology Molecular Diagnostics Portfolio, collects information from Lab Directors on their workforce, and on the volume of tests they conduct by cancer type and methodology of biomarker testing.

Pieter De Richter, Head of Ipsos Healthcare's Real World Evidence Portfolio in Asia Pacific and MENA, says the study, combined with the company's Molecular Diagnostics Monitor, which focuses on Oncologist and Pathologist perceptions and behaviour, provides a holistic, multi-stakeholder view of cancer biomarker testing.

Ipsos Healthcare operates in more than 40 countries and employs more than 700 professionals. Web site: www.ipsos.com .